Brief: ADC Therapeutics Announces Updates On Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Glofitamab Or Mosunetuzumab In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
04/04/2024 12:26
April 4 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES UPDATES ON LOTIS-7 CLINICAL
TRIAL
EVALUATING ZYNLONTA® IN COMBINATION WITH GLOFITAMAB OR
MOSUNETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL
NON-HODGKIN LYMPHOMA
* ADC THERAPEUTICS SA - IN DOSE ESCALATION PORTION (PART 1)
OF
LOTIS-7, NO DOSE-LIMITING TOXICITIES WERE OBSERVED ACROSS ALL
PATIENTS
Source text for Eikon: ID:nGNX9qQGzL
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview